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Abstract
Severe malaria occurs predominantly in young children and immunity to clinical disease is associated with cumulative
exposure in holoendemic settings. The relative contribution of immunity against various stages of the parasite life cycle that
results in controlling infection and limiting disease is not well understood. Here we analyse the dynamics of Plasmodium
falciparum malaria infection after treatment in a cohort of 197 healthy study participants of different ages in order to model
naturally acquired immunity. We find that both delayed time-to-infection and reductions in asymptomatic parasitaemias in
older age groups can be explained by immunity that reduces the growth of blood stage as opposed to liver stage parasites.
We found that this mechanism would require at least two components – a rapidly acting strain-specific component, as well
as a slowly acquired cross-reactive or general immunity to all strains. Analysis and modelling of malaria infection dynamics
and naturally acquired immunity with age provides important insights into what mechanisms of immune control may be
harnessed by malaria vaccine strategists.
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Introduction
Plasmodium falciparum (Pf) malaria in holoendemic areas is
characterized by high level parasitaemia and symptomatic
infections in early childhood, followed by the development of
semi-protective immunity that allows the persistence of low level
asymptomatic infections and appears to reduce the likelihood of
becoming infected if bitten by an infective mosquito. The
mechanisms mediating anti-infection and anti-disease immunity
are complex but are thought to include innate and adaptive
immune responses that limit both the liver and blood stage of the
parasite life cycle in the human host [1,2].
One approach to understanding acquired immunity to Pf-
malaria has been to study correlates of protection by measuring
point-prevalence levels of immunity and prospectively assessing
the infection status and clinical disease. A number of studies have
elaborated upon this approach by first treating patients with anti-
malarial drugs to eliminate blood-stage malaria infection, and then
observing the time to natural (re)-infection in an endemic setting
[3]. By measuring immune parameters at baseline, and observing
their association with time-to-infection, it may be possible to
identify the immune responses most important for protection from
malaria. A significant difficulty with these studies is that most
immune responses to malaria increase with age and after
cumulative exposure to malaria antigens, and so it is often unclear
whether measured responses actually mediate protection or are
merely a historical marker of past exposure [4,5]. Both antibody
specificity and isotype may play a role in protection [6,7] and
indeed the specific assay used to measure immune function can
lead to contradictory or inconsistent conclusions. For example,
antibodies that are reactive in an ELISA assay tend to increase
with age, but are often not correlated with protection when
corrected for age [8]. Antibodies detected using a functional assay
that measures inhibition of parasite growth show an increase with
age, and an association with protection from clinical disease, but
not from infection [9]. Surprisingly, growth inhibitory antibodies
(that can restrict parasite growth in vitro) are associated with a delay
in time-to-infection for individuals within a given age group, but
the level of inhibition decreases with age [3,10]. Independent of
these experimental studies, modeling of malaria infection has also
attempted to understand the possible cross-reactivity and molec-
ular targets of malaria immunity, using a heuristic approach based
on a qualitative assessment of the data
An alternative approach to understanding anti-malarial immu-
nity is to study the dynamics of infection and then predict how
these dynamics would be influenced by acquired immunity. That
is, by comparing the infection dynamics observed in susceptible
(children) in contrast to resistant (adult) populations, we can use a
reverse-engineering approach to understand the differences
observed in infection and growth, and predict what immune
mechanisms are compatible with such an outcome. Here we use
such a modeling approach to understand the effects of naturally
PLOS Computational Biology | www.ploscompbiol.org 1 October 2012 | Volume 8 | Issue 10 | e1002729
acquired immunity on the dynamics of P. falciparum malaria
infection in a cohort of 197 people from a holoendemic region of
western Kenya.
Materials and Methods
A treatment time-to-infection cohort study
The details of cohort study have been described elsewhere [3].
Briefly, upon entry into the study (day 0) study participants
(n = 201) were treated with CoartemH, which is expected to
eradicate blood stage infection but is not effective against liver
stage parasites [11]. Therefore, if a study participant was
parasitaemic at week two post-treatment, this was considered an
emerging liver stage infection and they were eliminated from
further study. After treatment, blood smears were monitored
weekly for 11 weeks by examination of thick and thin blood smears
using light microscopy for the presence of Pf-malaria parasites. In
addition, if weekly samples were not collected after week two post-
treatment, then the study participant was eliminated; thus leaving
197 remaining for analysis. The cohort was divided into four age
groups based on the immuno-epidemiology of malaria; C1
(children 1–4 years old (y.o.) were the least likely to have
developed anti-malarial immunity and thus most susceptible to
rapid infection; C2 (5–9 y.o.) have begun to develop partially
protective immunity though may have limited strain-specific
immunity; C3 (10–14 y.o.) have developed anti-malarial immunity
that should begin to contain a broader repertoire of strain-specific
immunity due to cumulative exposure; and A (adults.15 y.o.) who
have developed anti-malarial immunity that decreases the rate of
infection, parasite growth and provides coverage across many
strains. Fig. 1A shows the infection curves for each age group over
the 11 weeks of the study.
The dynamics of infection
The early stages of infection involve an infected bite, infection of
a liver cell, and maturation of the liver stage parasite over 6–7 days
[12]. After this, the infected liver cells rupture, releasing
approximately 20,000 merozoites [13]. These merozoites then
initiate the blood stage infection, and successive rounds of blood
stage replication follow, each lasting approximately 2 days. These
earliest events during human liver and early blood stage infection
are not measured in our cohort, and we first detect parasites when
their density in blood reaches our detection threshold (,40
parasites/ml). Both the rate of initiation of blood stage infection as
well as the rate of growth of blood stage immunity will affect the
time to first detection of infection (Fig. 1B). Liver stage immunity
acts to block some infected bites from reaching the blood stage,
and thus the initiation of the blood stage infection will occur with a
frequency less than or equal to the real infected biting rate, and
occur approximately seven days after the infected bite. Once blood
stage infection is initiated, parasites grow at a rate determined by
how many merozoites successfully invade new RBCs, and grow to
maturity over the two-day life-cycle. We might consider this the
‘parasite multiplication rate’ (PMR), which reflects the fold
increase in parasitaemia over the two day life cycle of an infected
RBC. Thus, the concentration (C) of parasites during their growth
in the blood stage can be described by formula
C(t)~Art=2,
where A is the initial concentration of parasitized RBC in blood
produced by the liver stage (estimated elsewhere [13]), r is the
PMR and t is the time in days passed after initiation of blood stage.
Incorporating the rate of initiation of blood stage infection (k), we
expect the proportion of uninfected individuals remaining at a
given time (S(t)) to follow the equation:
S(t)~
e{k(t{2logrT=A{t), tw2logrT=Azt
1, tƒ2logrT=Azt
(
ð1Þ
where T is the detection threshold and t is the first possible
moment of blood stage infection after treatment.
In our cohort, the youngest children are the most-susceptible to
infection (have the least immunity), and thus we use this group as a
baseline from which to observe the effects of age-acquired
immunity in the older cohorts. The infection curve of the youngest
children seems to conform well with the simple dynamics
described in equation (1) (Fig. 1.C). Thus, assuming that the
earliest initiation of the blood stage (t) is day 7 (due to the
pharmacodynamics of lumafantrine), we found the rate of
initiation of blood stage infection (k) at 0.066/day, with 95%
confidence interval (CI) of (0.056, 0.076), and PMR (r) of 5.9, CI
(3.145, 8.671) for the youngest age group. Using this fit to the
infection of the youngest children, we then attempt to find what
mechanisms of immunity can alter this infection curve to produce
the curves observed in older age groups.
Results
Modelling the effects of liver stage immunity
Previous work suggests that immunity may act anywhere in the
pre-erythrocytic stage to block sporozoite invasion [14] or kill
infected liver cells. Wherever it acts, the primary results of pre-
erythrocytic immunity will be to (i) reduce the proportion of
infected bites that lead to blood stage infection (reduce k), and/or
(ii) to reduce the number of infected liver cells that successfully
mature to release merozoites and initiate the blood stage (reduce
A).
From a modeling perspective, anything that reduces the
initiation of successful blood stage infection has the same effect –
it simply decreases the slope of our reinfection curve (which
Author Summary
Human malaria infections resulting in serious complica-
tions and death occur predominantly in young children,
and resistance is gradually acquired with repeated
exposure. Malaria parasites have two major stages within
the human host during its life cycle: an initial liver stage,
and the subsequent blood stage, where parasites replicate
in and destroy red blood cells. The mechanisms of
acquired resistance to severe malaria may involve immu-
nity to both the liver and blood stage parasites. However
the relative contribution of each type of immunity is not
yet understood. To gain novel insight, we have analysed
data from a malaria exposed cohort from western Kenya.
We used mathematical modeling to understand what form
of immunity is consistent with the observed rates of
reinfection in adults and children seen in the field study
data. We found that the reinfection pattern can be
completely explained by blood stage immunity. Moreover,
the blood stage immunity must consist of rapidly-induced
strain-specific immunity that clears individual infections,
and general immunity that accumulates slowly and
decreases the average parasite growth rate with age.
Understanding the dynamics of naturally acquired immu-
nity and infection provides important insights for effective
vaccine development.
The Dynamics of Acquired Immunity to Malaria
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remains in exponential form). Fig. 2.A. illustrates the predicted
effects of decreasing the rate of initiation of blood stage infection
and shows the best fits of a model that incorporates this change to
the cohort data. The fits are essentially a family of curves
commencing at the same time, and decreasing at different rates.
The best fit parameters and goodness of fit statistics are in the
[Text S4], (model 1). This is quite different from the observed
infection rates in two respects: (a) it does not capture the greater
delay until infection is observed in older children and adults, and
(b) it does not capture the convex part of the adults’ and older
children’s infection curve.
One may think that greater delay in detection of blood stage
infection in adults may be explained by other factors such as
increased blood volume in adults, or a decrease in the number of
infected liver cells surviving to maturity in adults (due to the effects
of cytotoxic T cell immunity killing [13] or growth inhibition [15]).
However, this is not adequate to explain the observed delay. The
number of infected liver cells is rarely higher then 10–14,
[13,16,17], and the blood volume differs by only a factor of
approximately 5, thus even combined they could explain at best a
delay of 4.7 days (using the PMR of the youngest age group 5.9). It
is clear that, in addition to underestimating the delay, pre-
erythrocytic immunity alone fails to account for the change in
shape of the curve associated with age and cumulative exposure.
The effects of blood stage immunity
Once the blood stage of infection is successfully initiated,
immunity may act on either the growth of the parasite within the
infected RBC or directly on the released merozoites to reduce the
rate of successful subsequent invasion events. Immunity acting at
these stages will have the effect of reducing the parasite
multiplication rate, and reduced PMR will lead to a greater delay
until infection is detected. However, reducing the PMR alone
affects the infection curves simply by shifting the curves to the
Figure 1. The dynamics of reinfection. Panel A. The rates of reinfection in the clinical cohort are shown for each age group over time. The
proportion uninfected is shown as a ‘survival curve’ for each age group. Patients were censored if they had missing values or were treated prior to
reinfection. Blue triangle and blue line - C1, green diamond and green line - C2, orange square and orange line - C3, red circle and red line - A. Panel B.
Schematic illustration of parasite growth in blood. Infection commences with an infected bite, followed by a liver stage of one week. Once the blood
stage commences, rapid parasite growth (high PMR) will lead to early detection on infection. Factors that slow parasite growth in the blood will delay
the time until detection. Panel C. Exponential fit to field study data for group C1.
doi:10.1371/journal.pcbi.1002729.g001
Figure 2. The impact of immunity on reinfection curves. The effects of liver stage immunity blocking a proportion of infected bites (A), or
blood stage immunity decreasing the growth of parasites (decreased PMR) (B) is shown. Liver stage immunity alone decreases the rate of new
infections, producing a family of exponential curves. Slower growth produces a family of curves shifted due to an increasing delay in detection. The
same biting rate is used for all age groups. Blue triangle and blue line- C1, green diamond and green line - C2, orange square and orange line - C3, red
circle and red line - A.
doi:10.1371/journal.pcbi.1002729.g002
The Dynamics of Acquired Immunity to Malaria
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right. That is, if the rate of successful initiation of the liver stage is
unaffected, the effect is only to change the time until parasite
density grows above the threshold but not to affect the infection
rate.
We attempted to fit our model assuming only the PMR changed
with age (Fig. 2.B). The best fit parameters and goodness of fit
statistics are in the [Text S4], (model 3).. It is once again clear that
although growth-inhibiting immunity can account for the delay in
infection, it fails to capture the shape of the infection curve. Even
combining the effects of liver and blood stage immunity fails to
capture the observed infection curves. For example, in the adult
infection curves, no combination of liver and blood stage
immunity can account for the delayed, slowly starting shoulder
of the infection curve, followed by an early period of high
infection, followed by a further slowing in infection rate (Fig. 1).
The effects of blood-stage immunity with a distribution
in parasite growth rates
The simple models above consider the effects of a fixed growth
rate within a given age group. However, the growth rate of
parasites is likely to vary between individuals as a result of a
combination of parasite strain and host factors such as intrinsic
immune maturation [18,19]. Therefore, rather than consider all
infections in an age group having the same growth rate [PMR=6,
for example], we investigated the effects of variation in the parasite
growth rate around the population mean within each group. For
simplicity we have assumed a normal distribution in PMR, and the
same standard deviation (as a proportion of the mean) for each age
group. We note that it is not essential that all groups have the same
coefficient of variation, however fitting the same parameter to all
reduces the number of parameters fitted by three (See [Text S1]
for a complete description of the mathematical model).
Using a simple assumption that all age groups have the same
biting rate and the same type of positive normal distribution of
growth rates (with the standard deviation the same proportion of
the mean PMR) we then fitted a theoretical infection function (2)
to the observed infection proportion, allowing only the mean PMR
to vary between age groups (note that a higher biting rate in adults
has been suggested by some [20] and can also be accommodated
in the model).
S k,m,p½  tð Þ~ 1{ 1{FN 1ð Þð Þ
Ðt
t
FE t{x{tð Þg x{tð Þdx, twt,
1, 0vtƒt:
8<
: ð2Þ
g (.) is the probability density function of the delay to detection,
g tð Þ~
2 T=Að Þ2=tln T=Að ÞfN T=Að Þ2=t
 
t2(1{FN 1ð Þ) , ð3Þ
fN(m,pm) (x) is the probability density function of a normal
distribution with parameters m and pm, and m is the mean PMR
in a given age group. Constant p is a positive number same for all
age groups. FE(k)(x) is the cumulative density function of an
exponential distribution with parameter k – the average number of
bites per day, which is also the same for all age groups.
The derivation of the theoretical infection function that
incorporates distribution in the time to infective bites and PMR
within the host for different age groups is shown in [Text S1]. The
best fit parameters and goodness of fit statistics are in the [Text
S4], (model 4).
Remarkably, allowing only the average PMR to vary between
age groups captures the main features of the natural infection
profiles. We see both the increasing delay with age, as well as the
early rapid increase in infection rates followed by an apparent
slowing down of the rate of infection (Fig. 3A). With this model of
a distribution in PMRs, we can now understand the unusual shape
of the adult infection curve: The early slow shoulder of the curve
represents the small fraction of infections that grow rapidly, and
are detected early (the right hand side of the distribution in
Fig. 3B). The rapid phase of infection is around the mean of the
PMR curve, and the apparent slowing represents the very slowly
growing infections, which are not detected during the 11 weeks of
analysis. Because of the distribution of growth rates, there is a
proportion of infections where the PMR ,1 (shaded in Fig. 3B),
implying the number of parasites decreases at each round of
infection (each currently infected RBC infects less than one RBC
in next round). In children, with mean PMR of <3.8, only a small
proportion of infections have PMR ,1. However, for the adults,
with mean PMR <1.35, a large proportion of bites (<24%) have
PMR ,1, which is why we see an apparent slowing of the
infection rate later in the study. We note that by contrast simply
allowing a distribution of the level of liver stage immunity alone
does not improve the fit of the liver stage model (see [Text S3] for
a detailed description of the model ).
Modelling naturally acquired immunity
Our analysis suggests that a model that can fit the data well is
one that assumes a distribution in PMRs within each age group,
and a decrease in mean PMRs with age. A key question that
follows is – could such a distribution with age arise from a known
mechanism of immunity? Similarly, we have considered above
only the relationship between PMR and time to detection of
infection. However, decreased PMR would also decrease the
observed levels of parasitaemia with age. Is the change in PMR
required to produce the reinfection curves consistent with the
change in parasitaemia levels with age? To answer this, we
developed a stochastic model of within-host immunity and parasite
growth to explore the effects of naturally acquired immunity. We
focused on the impact of immunity affecting parasite growth, and
further allowed that such immunity might either be strain-specific,
or ‘general’ (affecting all strains equally). In this context, a strain-
specific immunity may be defined by expression of variable
proteins such as var genes or immunologic targets proteins such as
merozoite or sporozoite surface antigens) that can vary across
strains. General immunity is a response (be it immune or
physiological – such as hyper-splenism) that acts equally on all
strains. A number of previous models of malaria immunity have
considered the effects of partially cross-reactive immune responses
[21,22,23,24]. However, we effectively model only the extremes of
‘completely strain-specific’ or ‘completely cross reactive’ responses
for simplicity.
In our model, strain-specific immunity arises as the result of the
infection with a certain strain and neutralises the parasites of this
strain only. General immunity arises as the result of infection with
any strain and it can neutralise parasites of any strain. The
acquisition rate of both types of immunity is proportional to
concentration of parasites in the blood. Without infection, the
existing level of immunity decays at some constant rate. Thus the
model has four parameters of immunity: for both strain-specific
immunity and general immunity we have a rate of increase in
immunity per unit parasite (denoted by a and c respectively), and a
rate of loss of immunity in the absence of parasite denoted
(denoted by b and d respectively). We also require three parasite
parameters: the mean number of bites per day k (biting rate), the
The Dynamics of Acquired Immunity to Malaria
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baseline multiplication rate r of the parasites, and the number of
different strains n. The basic equations of parasite – immunity
dynamics of the model are:
dPi
dt
~((1{h(Pi)) ln r=2{G{Si)Pi,
dSi
dt
~aPi{bh(Pi)Si,
dG
dt
~c
Xn
j~1
Pj{dh(
Xn
j~1
Pj)G,
i~1,:::,n:
ð4Þ
Here Pi is the concentration of parasites of the strain i, Si is the
strength of the i th strain specific immunity, i~1, . . . ,n. G is the
strength of the general immunity. The function h(.) is either one (if
the concentration of parasites,threshold) or zero (if the concen-
tration of parasites$threshold), and allows for the elimination of
parasites and the decay of immunity when the level of parasites
drops below a threshold Z (in this case 0.005 parasites/microlitre ).
A detailed description of the mathematical model is in the [Text
S2].
Using this model we can simulate the ‘life history’ of an
individual in a malaria endemic area. In the model, we start with
the assumption that all individuals are identical and lack immunity
at birth (t=0), and are then exposed to bites from different strains
arriving at random times, with a random order of strains (choosing
from our 50 notional strains), to which they then develop
immunity (ignoring the transient contribution of maternally-
derived immunity). Thus, the timing of bites and which strain is
inoculated is stochastic, but between bites the dynamics of
parasites and immunity is deterministic (as in equation 2).
Fig. 4 shows the dynamics of parasite infection and acquisition
of strain specific and general immunity by an individual, starting
from birth to one year [left panel] and five to six years [right
panel]. The top panels show the dynamics of parasite infection, as
different parasite strains (indicated by different colours) initiate
blood stage infection, grow, and then induce strain-specific
immunity, leading to their clearance. Given the long half-life of
strain-specific immunity and the absence of within-host parasite
antigen variation in our model, each new parasitemia peak
represents infection with a new strain. In addition to inducing
strain-specific immunity (bottom panels, coloured), these infections
also induce general immunity (solid black line), which accumulates
over time. By simulating the life history of a small population of
individuals (n = 50), we can then apply the concept of ‘treatment-
time-to-infection’ trials to the simulated individuals. That is, by
removing all blood stage parasites of individuals in different age
groups and observing the time until parasite levels reach our
detection threshold, we can simulate (re)-infection (Fig. 5 and 6).
Fig. 5 shows the dynamics of parasitaemia during (re)-infection
from the field study data (top) and the simulation (bottom), for four
subjects from each of the different age groups. Remarkably, the
simulation captures a number of the factors observed in our
observational study; firstly, the natural infection curves show
increasing delay with age and an increasing proportion of
individuals remaining uninfected. Secondly, the observed reduc-
tion in parasite levels in blood with age is also captured in the
model, indicating that the decreased PMR required to produce the
reinfection curves is consistent with the decreased PMR required
to produce the observed reduction in parasitaemia with age. (as
higher immunity means parasites are controlled at a lower
parasitaemia) (Fig. 5). Fig. 6A shows the infection curves for the
whole simulated population, and Fig. 6B compares the mean
parasitaemia for the field study data and simulation for different
ages. Importantly, the major factor that can account for both
delayed infection and lower parasitaemia in adults is simply a
reduced average growth rate of parasites with age and naturally
acquired immunity.
Discussion
Understanding the dynamics of immunity to malaria
A number of modelling studies have previously been applied to
understanding the dynamics of malaria infection and the impact of
immunity. Some of these studies have focused upon the dynamics
of experimental infection of neurosyphilis patients in the USA
during the early 20th century with both P. falciparum [25] and P.
vivax [26]. Such infections with P. falciparum often show a dynamic
of repeated recrudescence, in the absence of reinfection. Modelling
both infection rates and infection dynamics has also been applied
to more recent data on infection in naturally exposed individuals
[27,28]. The recent discovery of the molecular mechanisms of
Figure 3. A distribution in growth rates explains differences in reinfection curves. Panel A. Optimal fit of a model allowing variation only in
mean parasite multiplication rate (PMR) between groups. Panel B. The mean PMR for each group and the distributions. The shaded area at left
indicates where PMR ,1, and the parasite population does not grow, Panel C. Given the distribution in PMR, we can also calculate the distribution of
delay as a distribution of a function of a random variable. Blue triangle and blue line- C1, green diamond and green line - C2, orange square and
orange line - C3, red circle and red line - A.
doi:10.1371/journal.pcbi.1002729.g003
The Dynamics of Acquired Immunity to Malaria
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antigenic variation in P.falciparum has also driven studies modelling
the dynamics of immune interaction with an antigenically variable
pathogen [21,22,23,24]. In our study, we utilise field data on
malaria infection dynamics after a short treatment course in a
holoendemic region of Kenya. The estimated P. falciparum
infection rates are extremely high, especially amongst young
children, but consistent with the high entomological infection rates
measured in this area [29]and with the blood-stage infection rates
previously observed by others in similar studies [30,31]. The prior
treatment of patients gives an ideal opportunity to study malaria
incidence in the absence of recrudesence from prior infection.
However, there is a potential problem equating the measured time
to reinfection in treated, asymptomatic individuals with incidence
rates of new blood-stage infection in individuals living in highly
endemic areas, and then using these findings to make general
statements about acquired immunity to malaria. However, given
that children in this area are treated on average twice a year [32],
this is likely as natural an infection dynamic as can be readily
studied.
Fitting of a simple model of infection dynamics to the field data
on P. falciparum infection demonstrates that the observed rates of
infection with age are consistent with a form of immunity that
reduces the PMR of the parasite in blood. This mechanism of
blood-stage immunity reducing PMRs is consistent not only with
the dynamics of infection after treatment in different age groups,
but also with the observed reduction in peak parasitaemia with
Figure 4. Evolution of immunity over time. Panel A. The results of a stochastic simulation of acquired immunity are shown for one in silico
individual. Bites (coloured triangles) occur randomly with a fixed biting rate, and different strains (coloured, and numbered below) initiate infection.
Each infection induces and is cleared by strain-specific immunity (Panel B), which then wanes over time. General immunity (solid black line)
accumulates slowly over time. The accumulation of immunity in the first year (left panels) and aged 5–6 years (right panels) is shown.
doi:10.1371/journal.pcbi.1002729.g004
Figure 5. Modeling the dynamics of reinfection. The parasitaemia during reinfection in four individuals from the field study (top row) and in
four individuals in the simulation (bottom row) are shown. Each individual is shown as a different colour.
doi:10.1371/journal.pcbi.1002729.g005
The Dynamics of Acquired Immunity to Malaria
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older age groups (Fig. 6). Although clinical malaria was not
studied in this model, one might imagine a reduction in parasite
replication with age may also play some role in both the
observed reduction in episodes of severe malaria as well as an
apparent shift from acute to chronic infections with age. The
fact that the model fits well without invoking a need for liver-
stage immunity does not exclude a role for liver stage immunity,
but suggests it is not a major force shaping the observed
infection dynamics. By contrast, liver-stage immunity alone
would be expected to have relatively little impact on either the
delay or peak parasitaemia. The estimated PMR in this study
and their change with age are very consistent with published
studies of parasite growth in unexposed adults in the UK
(estimated to have a high PMR of approx 8–14/cycle [12,13]),
compared with the reported very low PMRs in malaria endemic
areas (1.6–3/cycle) [33,34].
Insights into specific and general immunity
Although the initial model was developed on the basis of a
number of heuristic assumptions, the model provides some useful
insights into the possible mechanisms of blood-stage immunity
induced from natural malaria infections. Firstly, ‘parasite clearing’
immunity must be highly strain-specific: That is, we often see one
parasite peak being cleared immediately before another peak
arises (Fig. 5, C1, top). Given the time taken for clearance and
growth, this means that we must have one parasite being cleared
while another grows. Thus the immune response mediating
clearance of individual parasite peaks must have the characteristics
of being both highly strain-specific, and rapidly induced. Although
this strain-specific response must be rapidly induced, the duration
of strain-specific immunity may be varied in the model, depending
on the number of strains used and the biting rate. That is, if there
are only a small number of immunologically distinct strains of
parasite, then the duration of immunity needs to be short – to
allow reinfection. However, if there are a large number of
immunologically distinct strains, the half-life of strain-specific
immunity could be considerably longer and still consistent with the
data. Thus we are not able to speculate on the relative duration of
strain-specific versus general immunity, as has been discussed
elsewhere [21,22,23,24].
The long timescale over which age-related immunity is acquired
suggests that whatever factor mediates this must have a long half-
life (since the time taken for the immunity level to reach its
maximum is related to the half-life of immunity). If specific
immunity were the only mechanism, then it would need to be
long-lived, and the age-associated acquisition of immunity would
simply be the progress from having immunity to a few strains, to
having immunity to most strains. However, the intermediate
phenotype here (having immunity to a proportion of strains) is
incompatible with the age and parasitaemia data. That is, if we
had immunity to 50% of strains, and no immunity to the other
50%, this would mean that 50% of bites would be blocked
(changing the reinfection curve as in Fig. 2A) and that
parasitaemia of the remaining strains would be ‘normal’. This is
clearly not consistent with the data, suggesting that although
strain-specific immunity is required to explain the clearance of
individual parasite peaks, it is not sufficient to explain age-
associated changes in reinfection and parasitaemia.
The alternative to a strain-specific immune response to
individual infection episodes is a general anti-parasite response
that decreases the growth of all strains. In contrast to specific
immunity, general immunity takes many years to acquire and
accumulates after repeated infections. Thus, each infection should
both induce only a small rise in general immunity, and it must be
long-lived. It is also clear that general immunity alone cannot
produce the observed infection dynamics, as this could not
simultaneously drive one parasite strain down while the other
grows. In broad terms, we might consider that an increase in
general immunity with time drives down the mean PMR of an age
group. The distribution in growth rates within an age group arises
due to strain-specific immunity, with individual strains (in different
individuals) having different growth rates due to the variable levels
of strain-specific immunity, which wanes over time after infection
with that strain.
Mechanisms of immunity
Clinical studies of immune correlates of protection from malaria
are often complicated and difficult to reconcile (reviewed in [8]).
Overall, antibody levels have been found to generally increase
with age and exposure, when measured by the ability to bind
Figure 6. Reinfection and parasitaemia with blood stage immunity. The dynamics of reinfection (A) and the mean parasitaemia (B) are
shown for the stochastic simulation of acquired blood stage immunity. Panel A. Mean (calculated every 7 days) of 5 simulations of the reinfection
curves of individuals with general and strain specific immunity with parameters listed in Table S2.1. in [Text S2]. Blue triangle and blue line- 0–4 y.o.,
green diamond and green line - 5–9 y.o., orange square and orange line - 10–14 y.o., red circle and red line - 15–30 y.o. Panel B. Average
concentration of parasites in blood in the field study data (left 4 bars) and in the simulated reinfection data presented in the panel A.
doi:10.1371/journal.pcbi.1002729.g006
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parasite antigens in ELISA. It has generally been difficult to
demonstrate a clear correlation with protection from parasitaemia,
as this is so strongly confounded by age. These antibody levels are
also long-lived, appearing to persist with a half-life up to 5–10
years [35]. However, it is difficult to differentiate between binding
antibodies exerting a direct protective effect, or merely acting as
biomarkers of past infections.
Our model does not address the particular mechanisms or
specificity of immunity. However, one prediction of the model is
that each patent infection is cleared by a highly strain-specific
response, as it is common that the clearance of one strain occurs
while infection with another strain is still growing. This is
consistent with early studies suggesting that growth-inhibitory
antibodies may be highly strain-specific when tested in clinical
isolates [36]. Interestingly, some growth-inhibitory antibodies
appear as a correlate of protection within an age group, but
paradoxically decrease with age [3,10]. It is interesting to note that
strain-specific immunity also paradoxically decreases with age in
our model, due to the increase in general immunity.
We note some difficulties with defining the term ‘strain’ in
malaria, as recent deep sequencing studies have suggested a wide
range of genotypes [37]. Moreover, even once the genetic
structure of malaria strains is resolved, the immunological
specificity and cross-reactivity of responses may be highly complex.
We do not use the term ‘cross-reactive immunity’ when describing
a factor that limits the growth of all strains, but instead prefer the
term ‘general immunity’. The concept of cross reactivity may tend
to imply specific antibodies that cross-react between different
strains. However, we do not wish to exclude other factors such as
an enlarged spleen may tend to decrease the PMR of all strains,
and may also play a role in protection.
The majority of cases of severe malaria occur amongst young
children in endemic areas, and age and persistent exposure
provide some level of immunity to both clinical symptoms, as well
as measured parasitaemia [38]. Although this age-associated
acquisition of immunity is known, clinical studies of immune
responses to malaria often struggle to identify the mechanisms of
protection [38]. We have employed an alternative strategy in an
attempt to deconstruct the mechanisms of naturally acquired
immunity based on the dynamics of infection in otherwise healthy
asymptomatic individuals. We find that simple pre-erythrocytic
immunity acting alone is inconsistent with the data, as is a highly
strain-specific form of blood-stage immunity, as both would have
the overall effect of merely decreasing the number of successful
infections. Instead, the observed dynamics of infection and
parasitaemia levels in a cohort of individuals from a holoendemic
area of western Kenya are consistent with the reduction in parasite
multiplication rate with age, leading to both a delay in the time
until infection is detected, as well as reduce the peak parasitaemia.
In terms of the clinical outcomes observed, our study suggests that
the reduced rate of clinical malaria and reduced rate of apparent
infection (measured at a particular threshold of parasitaemia
detection) may both be driven by a reduction in parasite growth
rate, independent of any real change in infection rate. Further
studies are required to deconvolute immunity that inhibits parasite
growth distinct from its ability to infect hepatocytes and
erythrocytes.
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